百令胶囊对Graves病患者T淋巴细胞亚群的影响

Effect of Bailing Capsule on T Lymphocyte Subsets in Patients with Graves’ Disease

摘要:

目的: 探讨观察百令胶囊对Graves 病(Graves' disease,GD) 患者T淋巴细胞亚群及远期预后的影响。方法: 选择GD患者60例,分为常规治疗组、百令胶囊治疗组,每组30例,常规治疗组予甲巯咪唑治疗,百令胶囊治疗组在常规治疗组治疗的基础上加用百令胶囊,4粒/次,3次/日,连续用药12个月,观察两组治疗前后外周血T淋巴细胞亚群、甲状腺功能、干扰素-γ(IFN-γ)、白细胞介素-4(IL-4)、自身抗体变化,停药后随访1年,观察GD复发率。结果: 治疗结束时两组甲状腺功能差异不显著,百令胶囊治疗组治疗后外周血CD4⁺,CD4/CD8,IFN-γ,促甲状腺激素受体抗体(TRAb)[CD4⁺(30.6±2.1)%,CD4/CD8(1.5±1.7), IFN-γ(25.8±4.2) μg·L^-1, TRAb(18.2±10.6)U·L^-1]·L^-1, TRAb(18.2±10.6)U·L^-1]较常规治疗组[(35.9±1.8)%,(1.7±1.3),(34.8±2.4)μg·L^-1,(25.9±8.8)U·L^-1]·L^-1,(25.9±8.8)U·L^-1]下降更明显,且差异有统计学意义(P<0.05), CD8⁺T细胞亚群数、IL-4水平升高更明显[CD8⁺(23.1±1.8)% vs (20.2±1.3)%, IL-4(14.8±3.2) μg·L^-1 vs (12.5±1.7) μg·L^-1]·L^-1 vs (12.5±1.7) μg·L^-1],且差异有统计学意义(P<0.05);停药1年后随访,百令胶囊治疗组16.7%,较常规治疗组40%复发率明显降低,差异有显著性意义(P<0.05)。结论: 百令胶囊能有效的调节GD患者细胞免疫,降低GD患者自身抗体水平。

Abstract:

Objective: To investigate the effect of Bailing capsule on T lymphocyte subsets in patients with Graves' disease(GD). Method: Sixty patients with GD were selected and randomly divided into 2 groups, routine group (n=30) was treated with Methimazole;the Bailing capsule group (n=30) was treated with Bailing capsule(4# Tid)combined with Methimazole. The levels of T-lymphocyte subsets,free triiodothyronine 3(FT3),FT4,sensitive thyroid stimulating hormone(sTSH),thyrotrophin receptor antibody(TRAb),interferon-γ(FN-γ),interleukin-4(IL-4) were measured in two group pre and post treatment.Follow-up 1 year after treatment,observe the recurrence rate of GD. Result: The thyroid function of the two groups was not significant after treatment. After treatment the CD4⁺T cells,CD4/CD8,IFN-γ,TRAb in the Bailing Capsule group [CD4⁺(30.6±2.1)%,CD4/CD8(1.5±1.7), IFN-γ(25.8±4.2)μg·L^-1, TRAb(18.2±10.6)U·L^-1] was decreased more significantly than routine group[(35.9±1.8)%,(1.7±1.3),(34.8±2.4)μg·L^-1,(25.9±8.8)U·L^-1]. After treatment the CD8⁺T cells and IL-4 in the Bailing capsule group was increased more significantly than routine group[CD8⁺(23.1±1.8)% vs (20.2±1.3)%, IL-4(14.8±3.2) μg·L^-1 vs(12.5±1.7) μg·L^-1] (P<0.05). Follow-up 1 year after withdrawal,the Bailing capsule group than the c routine group recurrence rate was significantly lower(16.7% VS40%)(P<0.05). Conclusion: The Bailing capsule can effectively regulate the GD patient's cellular immunity and reduce autoantibody levels in GD patients.